• Lupin submits New Drug Application for Etanercept biosimilar in Japan biospectrumasia
    May 10, 2018
    “After significant investment in our biotechnology R&D division over the years, this is the first biosimilar for regulated markets developed in-house at Lupin and the first ever complex fusion protein like etanercept in regulated markets by an Indian phar
PharmaSources Customer Service